Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Breast (Edinburgh, Scotland)|April 30, 2023
Hypofractionation: The standard for external beam breast irradiationAdrian Murray Brunt, Joanne Susan Haviland
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|September 8, 2016
Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancerAdrian Murray Brunt, Susan Lupton, Karen Thorley, et al.
The Indian Journal of Surgery|August 25, 2020
Breast Cancer Management Guidelines During COVID-19 PandemicManoj Gowda S, Kirti Katherine Kabeer, Sadaf Jafferbhoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2019
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical TrialElizabeth A Mittendorf, Biao Lu, Michelle Melisko, et al.
Pilot and Feasibility Studies|March 1, 2022
The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trialJenny Ingram, Lucy Beasant, John Benson, et al.
Breast Cancer Research and Treatment|November 17, 2022
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysisDavid Glynn, Judith Bliss, Adrian Murray Brunt, et al.
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
The Lancet. Oncology|January 1, 2022
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancerIcro Meattini, Carlotta Becherini, Liesbeth Boersma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2020
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast CancerAdrian Murray Brunt, Joanne S Haviland, Mark Sydenham, et al.
Pageof 2